Strong Tower Advisory Services Buys 397 Shares of Eli Lilly and Company $LLY

Key Points

• Strong Tower Advisory Services has increased its stake in Eli Lilly and Company by 3.9%, acquiring an additional 397 shares during the second quarter, making the company its 18th largest holding.
• Several hedge funds showed significant activity with Eli Lilly, including WestEnd Advisors, which increased its stake by 210% in the first quarter.
• Eli Lilly's recent earnings report revealed a 37.6% increase in revenue year-over-year, reporting $6.31 EPS for the last quarter, beating consensus estimates.

Strong Tower Advisory Services lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,621 shares of the company's stock after acquiring an additional 397 shares during the period. Eli Lilly and Company makes up about 1.6% of Strong Tower Advisory Services' investment portfolio, making the stock its 18th largest holding. Strong Tower Advisory Services' holdings in Eli Lilly and Company were worth $8,279,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. WestEnd Advisors LLC lifted its stake in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at $27,000. Citizens National Bank Trust Department lifted its stake in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company in the first quarter valued at $40,000. Finally, TD Capital Management LLC lifted its stake in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after acquiring an additional 31 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on LLY shares. Leerink Partners restated a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. JPMorgan Chase & Co. cut their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday, September 16th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. Finally, Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $948.56.

Insider Buying and Selling

In related news, Director Jamere Jackson acquired 200 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the transaction, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Daniel Skovronsky acquired 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $833.08 on Friday. The firm has a 50 day moving average of $742.42 and a 200-day moving average of $766.36. The stock has a market capitalization of $788.47 billion, a PE ratio of 54.45, a PEG ratio of 1.19 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the previous year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.